Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma

Immune checkpoint inhibition has been approved for front-line treatment of metastatic bladder cancer in patients who are cisplatin-ineligible and demonstrate programmed death-ligand 1 (PD-L1) positivity. This approval followed the positive results of IMvigor210 and KEYNOTE-052 studies. Immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jason R., Krane, Spencer, Garcia, Jorge, Barata, Pedro C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053833/
https://www.ncbi.nlm.nih.gov/pubmed/33948120
http://dx.doi.org/10.1177/17562872211004797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053833/
https://www.ncbi.nlm.nih.gov/pubmed/33948120
http://dx.doi.org/10.1177/17562872211004797

Ejemplares similares